| Active, not recruiting | 2/3 | 186 | NA | Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 05/25 | 05/25 | | |
VANTAGE, NCT05050136: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis |
|
|
| Recruiting | 2 | 180 | Europe, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc. | Primary Biliary Cholangitis, PBC | 12/25 | 12/25 | | |